Effects of Hepazym-immunotherapy in chronic hepatitis B patient treated with Baraclude (Entecavir)

There are different potential mechanisms for how HBV can be inhibited. Mechanisms include an antiviral and immune modulating approach with natural substances like Hepazym. One of the primary ways in which Hepazym can benefit your health is in its ability to interact with, and modulate the immune system. The ability of a substance to modulate the immune system is extremely useful. Modulation is a term used to describe the process of reducing the extremes of cellular activity – either stimulation or inhibition. Immune modulating substances have the ability to work in both directions. They can boost the immune system when it is depressed (referring to conditions such as chronic fatigue) and can also suppress the immune system when it is over-stimulated (such as in the case of autoimmune diseases like lupus or rheumatoid arthritis).

Most immune modulating agents work by improving inter-cellular communication. One way that cells communicate is by presenting on their surface complex, information-rich protein macromolecules linked with molecules of saccharides (polysaccharides). An inter-cell “message” depends on the structure of saccharides. Researchers believe that people with chronic hepatitis B do not produce mature or adequate numbers of dendritic cells and therefore cannot eradicate the viral infection. Hepazym modulates and supports the immune system in a number of ways. It may cause an increase in the number of white blood cells, which are an integral part of the body’s natural immune system.

Combining elements of antiviral and immune modulating natural substances may help rid the body of the hepatitis B virus. Antivirals or nucleoside analogues are designed to deliberately interfere with HBV’s DNA so it can’t reproduce itself. There are 7 approved medications for chronic HBV infection: 5 oral nucleoside/nucleotide analogues (lamivudine, entecavir, telbivudine, adefovir, and tenofovir) and 2 injectable therapies (interferon alfa-2b and pegylated interferon alfa-2a). Baraclude (Entecavir) is an oral prescription antiviral medication used in the treatment of chronic HBV infection in adults with evidence of active viral replication and either evidence of persistent elevations in serum aminotransferases , AST (SGOT) and ALT (SGPT), or histologically active disease, but many patients fail to respond. Currently there is no cure for HBV. Antiviral drugs will not cure HBV. This has prompted a search for effective alternative therapies.

Recently, a patient (male, age 34, South Korean) with chronic hepatitis B treated with 0.5 mg per day of Baraclude (Entecavir) has taken Hepazym 50 ml (10 ml 5 times) a day for 6 weeks to spur the immune system. He was diagnosed with Heptitis B 13 years ago. His ALT (SGPT) levels have been consistently elevated, indicating that the liver is not functioning properly and that the hepatitis viral infection is damaging liver cells.

Blood test results: Oct. 2010

AST (SGOT): 53 (Normal range <40)

ALT (SGPT): 101 (Normal range <45)

HBV DNA: 3350 copies

HbeAg- negative


Blood test results: Nov 19, 2010

AST (SGOT): 40 (Normal range <40)

ALT (SGPT): 119 (Normal range <45)

HBV DNA: 357 copies

HbeAg- negative


Blood test results: Jan 12, 2011

6 weeks after taking Hepazym, this patient responded with significant decreases in ALT (GPT) levels from 119 to 26. He had a rapid increase in WBC (white blood cells) from 4.5 to 7.5. He has always had a low WBC. HBV viral load was undetectable. His chronic fatigue symptoms disappeared within 2 days after being taken Hepazym.

AST (SGOT): 39 (Normal range <40)

ALT (SGPT): 26 (Normal range <45)

HBV DNA: 0.13

HBeAg- negative


WBC (white blood cells): increased from 4.5 to 7.5

HBsAb: 1.00 (HBsAb level was increased to 1.00, but a protective level is more than 10 mIU/ml). This patient will continue Hepazym-immunotherapy for the next 10 weeks.

P.S: Mar 4, 2011 Blood test results

HBsAb (HepB surface antibody) levels elevated to 3. It means the desired immunity (protective antibodies to Hepatitis B) is developing. The development of immunity means that immunological memory has been acquiring. This is the time during which seroconversion occurs. The body is recognizing the HBV virus and producing antibodies to try to fight the infection. Serum HBsAg, AST (GOT) and ALT (GPT) levels showed increase during the period of seroconversion.

Comments are closed.